Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vonoprazan + amoxicillin + berberine
- Development stage
- Unknown
- Lead developer
- Nanjing First Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of vonoprazan, amoxicillin, and berberine, being investigated for the dual purpose of eradicating Helicobacter pylori (Hp) infection and improving metabolic syndrome parameters. Vonoprazan is a potassium-competitive acid blocker (P-CAB) that provides potent and sustained suppression of gastric acid, which is essential for the stability and efficacy of antibiotics in the stomach. Amoxicillin is a beta-lactam antibiotic that targets the bacterial cell wall of Hp. Berberine is a plant-derived alkaloid known for its antimicrobial properties and its ability to modulate metabolic pathways and the gut microbiota. The rationale for this combination is that Hp eradication, enhanced by the metabolic and prebiotic-like effects of berberine, may lead to improvements in insulin resistance, dyslipidemia, and chronic inflammation associated with metabolic syndrome.
- Other names
- Vonoprazan-Amoxicillin with Berberine
02
Targets
UreaseNAT (Arylamine N-acetyltransferase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on vonoprazan + amoxicillin + berberine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vonoprazan + amoxicillin + berberine.